ABLI Stock Overview
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.28|
|52 Week High||kr0.76|
|52 Week Low||kr0.22|
|1 Month Change||6.15%|
|3 Month Change||-26.98%|
|1 Year Change||-61.04%|
|3 Year Change||-85.41%|
|5 Year Change||-94.03%|
|Change since IPO||-95.75%|
Recent News & Updates
|ABLI||SE Biotechs||SE Market|
Return vs Industry: ABLI underperformed the Swedish Biotechs industry which returned -22.8% over the past year.
Return vs Market: ABLI underperformed the Swedish Market which returned -23.9% over the past year.
|ABLI Average Weekly Movement||10.1%|
|Biotechs Industry Average Movement||9.7%|
|Market Average Movement||7.3%|
|10% most volatile stocks in SE Market||12.7%|
|10% least volatile stocks in SE Market||4.6%|
Stable Share Price: ABLI is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ABLI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.
Abliva Fundamentals Summary
|ABLI fundamental statistics|
Is ABLI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABLI income statement (TTM)|
|Cost of Revenue||kr105.51m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 19, 2022
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-82,161.59%|
How did ABLI perform over the long term?See historical performance and comparison
Is ABLI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ABLI?
Other financial metrics that can be useful for relative valuation.
|What is ABLI's n/a Ratio?|
Price to Book Ratio vs Peers
How does ABLI's PB Ratio compare to its peers?
|ABLI PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
Price-To-Book vs Peers: ABLI is expensive based on its Price-To-Book Ratio (14.5x) compared to the peer average (2.3x).
Price to Earnings Ratio vs Industry
How does ABLI's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: ABLI is expensive based on its Price-To-Book Ratio (14.5x) compared to the Swedish Biotechs industry average (2.3x)
Price to Book Ratio vs Fair Ratio
What is ABLI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||14.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate ABLI's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ABLI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ABLI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ABLI's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Abliva forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Abliva has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Abliva performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABLI is currently unprofitable.
Growing Profit Margin: ABLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABLI is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare ABLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: ABLI has a negative Return on Equity (-616.83%), as it is currently unprofitable.
Discover strong past performing companies
How is Abliva's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ABLI's short term assets (SEK27.3M) exceed its short term liabilities (SEK17.3M).
Long Term Liabilities: ABLI's short term assets (SEK27.3M) exceed its long term liabilities (SEK24.2M).
Debt to Equity History and Analysis
Debt Level: ABLI is debt free.
Reducing Debt: ABLI has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABLI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ABLI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4% each year
Discover healthy companies
What is Abliva current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABLI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ABLI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ellen Donnelly (48 yo)
Dr. Ellen K. Donnelly, Ph D has been Chief Executive Officer at Abliva AB (publ) since February 03, 2021. She serves as Independent Director at Modus Therapeutics Holding Ab since 2020.Dr. Donnelly has be...
CEO Compensation Analysis
Compensation vs Market: Ellen's total compensation ($USD382.79K) is above average for companies of similar size in the Swedish market ($USD246.34K).
Compensation vs Earnings: Insufficient data to compare Ellen's compensation with company performance.
Experienced Management: ABLI's management team is seasoned and experienced (6.6 years average tenure).
Experienced Board: ABLI's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABLI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 162.1%.
Abliva AB (publ)'s employee growth, exchange listings and data sources
- Name: Abliva AB (publ)
- Ticker: ABLI
- Exchange: OM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr291.539m
- Shares outstanding: 1.06b
- Website: https://abliva.com
Number of Employees
- Abliva AB (publ)
- Medicon Village
- Skåne County
- 223 81
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.